Printer Friendly Printed from http://www.researchandmarkets.com/reports/552706 Does the Treatment of Huntingtons Disease Represent a Commercial Opportunity? Description: Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction. No drugs are approved to treat the disorder, leaving a high level of unmet need. Commercial opportunity abounds, but the small patient population deters some companies. However, because of novel treatment approaches, interest in HD research is growing and companies may be able to tap into the enormous commercial potential, especially if a drug can treat multiple neurological diseases. Questions Answered in This Spectrum Report: -Huntington’s disease has a small patient population across all markets. What are the advantages and disadvantages for drug developers? What effect does orphan-drug status have on a drug’s potential? -No therapies are approved specifically for HD; all current therapies are used off-label and provide only symptomatic relief. Which drugs are being investigated in clinical trials? What are the difficulties? When will a drug launch for HD? -Novel treatment approaches including disease-modifying stem-cell and gene therapies are making some headway. What companies are investigating HD treatments and what are the most promising treatment approaches? At what stage are these treatments, and what are the chances of their launching for HD? Scope: -Overview of Huntington’s disease: genetics, pathophysiology, epidemiology, symptoms, and diagnosis. -Current treatment approach: no therapies are approved for HD; several drugs are used off-label to treat symptoms. -Emerging therapies: disease-modifying agents, including Amarin’s Miraxion (Phase III) and Avicena’s HD-02 (Phase II), and symptomatic therapies, including Prestwick’s Xenazine (preregistered) and NeuroSearch’s ACR-16 (Phase II). -Novel treatment approaches: stem-cell transplantation and gene therapy. -Challenges and outlook: the future of the HD market. Contents: Executive Summary Strategic Considerations Stakeholder Implications Introduction Overview of Huntington’s Disease The Genetics of Huntington’s Disease Pathophysiology Disease Onset, Symptoms, and Diagnosis Epidemiology and Orphan Disease Status Current Treatment Strategies Emerging Therapies Disease-Modifying Agents Amarin’s Miraxion Avicena’s HD-02 MethylGene and EnVivo’s Phenylbutyrate Neurotrophic Factors: BDNF, GDNF, CNTF Symptomatic Emerging Therapies Prestwick Pharmaceuticals’ Xenazine NeuroSearch’s ACR-16 Sanofi -Aventis’s Rilutek Medivation’s Dimebon Challenges and Opportunities Tables: 1 Inheritance Patterns of Huntington’s Disease 2 Effect of CAG Repeats on Huntington’s Disease Development 3 Agents in Commercial Development for the Treatment of Huntington’s Disease 4 Agents Under Academic Investigation for the Treatment of Huntington’s Disease Figures: 1 Brain Structures Implicated in Huntington’s Disease 2 Prevalence of Huntington’s Disease in Select Geographic Regions Sidebars: Novel Approaches to the Treatment of Huntington’s Disease: Stem-Cell Transplantation Novel Approaches to the Treatment of Huntington’s Disease: Gene Therapy Companies Mentioned -Abbott -Amarin -Amgen -AstraZeneca -Avicena -Bristol-Myers Squibb -Carlsson Research -Ceregene -Edison Pharmaceuticals -Eli Lilly -Endo Pharmaceuticals -EnVivo -Janssen -Medivation -MethylGene -NeuroSearch -Novartis -Pfizer -Prestwick Pharmaceuticals -Renovis -Sanofi -Aventis -Wyeth Products Mentioned: -ACR-16 -Amantadine (Symmetrel) -Artane (trihexyphenidyl) -Atomoxetine (Strattera) -CERE-120 -Citalopram (Celexa) -CoEnzyme Q10 -Depakene (valproic acid) -Depakote (valproic acid and divalproex sodium) -Dimebon -HD-02 -Memantine (Namenda) -Minocycline -Miraxion -NXY-059 -Phenylbutyrate -Prozac (fl uoxetine) -Rilutek (riluzole) -Risperdal (risperidone) -SER-AP-ES (reserpine) -Seroquel (quetiapine) -Sinemet (levodopa) -Xenazine (tetrabenazine) -Zoloft (sertraline) Ordering: Order Online - visit http://www.researchandmarkets.com/reports/552706 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 09:14:41 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Does the Treatment of Huntingtons Disease Represent a Commercial Opportunity? Web Address: http://www.researchandmarkets.com/reports/552706 Office Code: OCHGMJPLORZ Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) - Single User €3,071.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 09:14:41 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World